BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15711801)

  • 1. Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes.
    Yamaguchi N; Ito Y; Ohyashiki K
    Ann Hematol; 2005 Jun; 84(6):383-8. PubMed ID: 15711801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
    Travaglino E; Benatti C; Malcovati L; Della Porta MG; Gallì A; Bonetti E; Rosti V; Cazzola M; Invernizzi R
    Eur J Haematol; 2008 Mar; 80(3):216-26. PubMed ID: 18081721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decline in antibiotic enzyme activity of neutrophils is a prognostic factor for infections in patients with myelodysplastic syndrome.
    Ito Y; Kawanishi Y; Shoji N; Ohyashiki K
    Clin Infect Dis; 2000 Nov; 31(5):1292-5. PubMed ID: 11073768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
    Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
    Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
    Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ; Zhang X; Zhu WL; Huang Y
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
    Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
    Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
    Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
    Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant elevation of plasma matrix metalloproteinase-9 level and its ratio to matrix metalloproteinase-2 in patients with pelvic inflammatory disease.
    Wang PH; Tsai HT; Tee YT; Lin LY; Yang SF; Hsieh YS
    Fertil Steril; 2009 Nov; 92(5):1679-84. PubMed ID: 18937938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
    Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
    Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
    Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome.
    Cordoba I; Gonzalez-Porras JR; Such E; Nomdedeu B; Luño E; de Paz R; Carbonell F; Vallespi T; Ardanaz M; Ramos F; Marco V; Bonanad S; Sanchez-Barba M; Costa D; Bernal T; Sanz GF; Cañizo MC
    Leuk Res; 2012 Mar; 36(3):287-92. PubMed ID: 22133642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation.
    Eliason JL; Hannawa KK; Ailawadi G; Sinha I; Ford JW; Deogracias MP; Roelofs KJ; Woodrum DT; Ennis TL; Henke PK; Stanley JC; Thompson RW; Upchurch GR
    Circulation; 2005 Jul; 112(2):232-40. PubMed ID: 16009808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
    Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.